BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. SPCX
3. DSX
4. GNK
5. III
6. SAN
7. TTEC
8. SNY
9. DAL
10. AWK

Go back to BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
(NASDAQ: BTAI) Delayed: 1.20 +0.01 (0.84%)
Previous Close $1.19    52 Week High $ 
Open $1.20    52 Week Low $ 
Day High $1.23    P/E N/A 
Day Low $1.18    EPS $ 
Volume 439,370